Jump to section
To raise the frequency of the collective consciousness by revolutionizing the mental health industry through the combination of psychedelic medicine, innovative therapeutic modalities, scientific research and cutting-edge neuroscience.
The clinical use of ketamine in the US has been FDA-approved since 1970. Since then, it’s been found to be effective in the treatment of depression and anxiety. Now it’s beginning to go mainstream. Wonder Sciences is pushing to combine ketamine therapy with the new vogue for telemedicine services, and also branch out into research and development for more psychedelics.
It’s not clear that the research side has seen much development, but the telemedicine ketamine treatment service is nicely fleshed out - even if customer numbers are hard to come by. Not a moment too soon, too: a crop of psychedelics startups has emerged recently, hoping to cash in on the increased demand for alternative off-label therapeutics.
Field Trip, Nue Life, and mindbloom are all direct competitors, and a number of companies even boast training courses for how to set up ketamine therapy startups more broadly - so Wonder Sciences will face stiff competition. So far, however, it wins out on price; and it reports a higher bar for eligibility than competitors, which customers leery about the process may be attracted to.
Freddie
Company Specialist at Welcome to the Jungle
Ryan Magnussen
(CEO)Has previously founded bungee jumping company Vertical Addictions, digital agency Zentrope Partners, entertainment production company Ripe Digital Entertainment, non-profit Conscious Society, and served as CEO of Grail, Inc.